However, several other tumor vaccines are currently being evaluated in clinical trials for lung tumors, and those target entities (mostly antigens or proteins) that are specific or highly abundant in lung cancer, such as 5T4, CEA, mesothelin, survivin, NY-ESO-1, telomerase, WT1, EGFR pathway proteins, in addition to personalized neoantigens and tumor-associated antigens (TAA) (which are further described below) (30, 93, 94). Here, EGFR is linked to lung cancer.